Donia Macartney-Coxson

Donia Macartney-Coxson

Auto-generated profile, based on publicly available information

Donia Macartney-Coxson

Institute of Environmental Science and Research, Health Group

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2001 in Oncogene
Verified
Journal Article
Closed access
PDF file
AAAngelo Agathanggelou
Angelo Agathanggelou
SHSofia Honorio
Sofia Honorio
DMDonia P Macartney
Donia P Macartney
AMAlonso Martinez
Alonso Martinez
ADAshraf Dallol
Ashraf Dallol
FLFarida Latif
Farida Latif

22 January 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
MBMiles C Benton
Miles C Benton
AJAlice Johnstone
Alice Johnstone
DEDavid Eccles
David Eccles
BHBrennan Harmon
Brennan Harmon
MHMark T Hayes
Mark T Hayes
DMDonia Macartney-Coxson
Donia Macartney-Coxson
Background: Environmental factors can influence obesity by epigenetic mechanisms. Adipose tissue plays a key role in obesity-related metabolic dysfunction, and gastric bypass provides a model to investigate obesity and weight loss in humans. Results: Here, we investigate DNA methylation in adipose tissue from obese women before and after gastric bypass and significant weight loss. In total, 485,577 CpG sites were profiled in matched, before and after weight loss, subcutaneous and omental adipose tissue. A paired analysis revealed significant differential methylation in omental and subcutaneous adipose tissue. A greater proportion of CpGs are hypermethylated before weight loss and increased methylation is observed in the 3′ untranslated region and gene bodies relative to promoter regions. Differential methylation is found within genes associated with obesity, epigenetic regulation and development, such as CETP, FOXP2, HDAC4, DNMT3B, KCNQ1 and HOX clusters. We identify robust correlations between changes in methylation and clinical trait, including associations between fasting glucose and HDAC4, SLC37A3 and DENND1C in subcutaneous adipose. Genes investigated with differential promoter methylation all show significantly different levels of mRNA before and after gastric bypass. Conclusions: This is the first study reporting global DNA methylation profiling of adipose tissue before and after gastric bypass and associated weight loss. It provides a strong basis for future work and offers additional evidence for the role of DNA methylation of adipose tissue in obesity.

1 October 1998 in Journal of Molecular Biology
Verified
Journal Article
Closed access
PTPeter B Thorsted
Peter B Thorsted
DMDonia P Macartney
Donia P Macartney
PAParveen Akhtar
Parveen Akhtar
AHAnthony S Haines
Anthony S Haines
NANasima Ali
Nasima Ali
CTChristopher M Thomas
Christopher M Thomas

21 August 2017 in Obesity
Verified
Journal Article
Open access
PDF file
AJAngela Jones
Angela Jones
Kirsty DanielsonKirsty Danielson
Kirsty Danielson
MBMiles C. Benton
Miles C. Benton
OZOlivia Ziegler
Olivia Ziegler
RSRavi Shah
Ravi Shah
DMDonia Macartney‐Coxson
Donia Macartney‐Coxson
Objective: Extracellular microRNAs (miRNAs) represent functional biomarkers for obesity and related disorders; this study investigated plasma miRNAs in insulin resistance phenotypes in obesity.Methods: One hundred seventy‐five miRNAs were analyzed in females with obesity (insulin sensitivity, n = 11; insulin resistance, n = 19; type 2 diabetes, n = 15) and without obesity (n = 12). Correlations between miRNA level and clinical parameters and levels of 15 miRNAs in a murine obesity model were investigated.Results: One hundred six miRNAs were significantly (adjusted P ≤ 0.05) different between controls and at least one obesity phenotype, including miRNAs with the following attributes: previously reported roles in obesity and altered circulating levels (e.g., miR‐122, miR‐192); known roles in obesity but no reported changes in circulating levels (e.g., miR‐378a); and no current reported role in, or association with, obesity (e.g., miR‐28‐5p, miR‐374b, miR‐32). The miRNAs in the latter group were found to be associated with extracellular vesicles. Forty‐eight miRNAs showed significant correlations with clinical parameters; stepwise regression retained let‐7b, miR‐144‐5p, miR‐34a, and miR‐532‐5p in a model predictive of insulin resistance (R2 = 0.57, P = 7.5 × 10−8). Both miR‐378a and miR‐122 were perturbed in metabolically relevant tissues in a murine model of obesity.Conclusions: This study expands on the role of extracellular miRNAs in insulin‐resistant phenotypes of obesity and identifies candidate miRNAs not previously associated with obesity.

12 December 2013 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
MGMC Graves
MC Graves
MBM Benton
M Benton
RLRa Lea
Ra Lea
MBM Boyle
M Boyle
LTL Tajouri
L Tajouri
JLJ Lechner-Scott
J Lechner-Scott
Background: Multiple sclerosis (MS) is thought to be caused by T-cell mediated autoimmune dysfunction. Risk of developing MS is influenced by environmental and genetic factors. Modifiable differences in DNA methylation are recognized as epigenetic contributors to MS risk and may provide a valuable link between environmental exposure and inherited genetic systems. Objectives and methods: To identify methylation changes associated with MS, we performed a genome-wide DNA methylation analysis of CD4+ T cells from 30 patients with relapsing–remitting MS and 28 healthy controls using Illumina 450K methylation arrays. Results: A striking differential methylation signal was observed at chr. 6p21, with a peak signal at HLA-DRB1. After prioritisation, we identified a panel of 74 CpGs associated with MS in this cohort. Most notably we found evidence of a major effect CpG island in DRB1 in MS cases ( pFDR < 3 × 10−3). In addition, we found 55 non-HLA CpGs that exhibited differential methylation, many of which localise to genes previously linked to MS. Conclusions: Our findings provide the first evidence for association of DNA methylation at HLA-DRB1 in relation to MS risk. Further studies are now warranted to validate and understand how these findings are involved in MS pathology.

1 July 2008 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DMDonia P Macartney-Coxson
Donia P Macartney-Coxson
KHKylie A Hood
Kylie A Hood
HSHong-Jun Shi
Hong-Jun Shi
TWTeresa Ward
Teresa Ward
AWAnna Wiles
Anna Wiles
SRSerena Rooker
Serena Rooker
Background: Mortality from colorectal cancer is mainly due to metastatic liver disease. Improved understanding of the molecular events underlying metastasis is crucial for the development of new methods for early detection and treatment of colorectal cancer. Loss of chromosome 8p is frequently seen in colorectal cancer and implicated in later stage disease and metastasis, although a single metastasis suppressor gene has yet to be identified. We therefore examined 8p for genes involved in colorectal cancer progression. Methods: Loss of heterozygosity analyses were used to map genetic loss in colorectal liver metastases. Candidate genes in the region of loss were investigated in clinical samples from 44 patients, including 6 with matched colon normal, colon tumour and liver metastasis. We investigated gene disruption at the level of DNA, mRNA and protein using a combination of mutation, semi-quantitative real-time PCR, western blotting and immunohistochemical analyses. Results: We mapped a 2 Mb region of 8p21-22 with loss of heterozygosity in 73% of samples; 8/11 liver metastasis samples had loss which was not present in the corresponding matched primary colon tumour. 13 candidate genes were identified for further analysis. Both up and down-regulation of 8p21-22 gene expression was associated with metastasis. ADAMDEC1 mRNA and protein expression decreased during both tumourigenesis and tumour progression. Increased STC1 and LOXL2 mRNA expression occurred during tumourigenesis. Liver metastases with low DcR1/TNFRSF10C mRNA expression were more likely to present with extrahepatic metastases (p = 0.005). A novel germline truncating mutation of DR5/TNFRSF10B was identified, and DR4/TNFRSF10A SNP rs4872077 was associated with the development of liver metastases (p = 0.02). Conclusion: Our data confirm that genes on 8p21-22 are dysregulated during colorectal cancer progression. Interestingly, however, instead of harbouring a single candidate colorectal metastasis suppressor 8p21-22 appears to be a hot-spot for tumour progression, encoding at least 13 genes with a putative role in carcinoma development. Thus, we propose that this region of 8p comprises a metastatic susceptibility locus involved in tumour progression whose disruption increases metastatic potential.